Patient characteristics
Characteristic . | Data . |
|---|---|
| Sex, no. patients | |
| Male | 16 |
| Female | 13 |
| Median age, y (range) | 73 (67-82) |
| Median ECOG performance status, (range) | 1 (1-3) |
| Median d from diagnosis to trial entry (range) | 21 (6-166) |
| FAB type, no. patients | |
| MO | 2 |
| M1 | 7 |
| M2 | 7 |
| M4 | 6 |
| M5 | 1 |
| M6 | 3 |
| Not classified | 3 |
| Cytogenetic risk group, no. patients | |
| Adverse | 5 |
| Intermediate | 23 |
| Favorable | 1 |
| FLT3 mutation status, no. patients | |
| Internal tandem duplication mutation | 2 |
| Tyrosine kinase domain mutation | 3 |
| Wild type | 24 |
| Median presenting WBC count, × 109/L (range) | 6.1 (0.8-140.7) |
| Prior therapy, no. patients | |
| Oral hydroxyurea | 5 |
| No prior treatment | 24 |
Characteristic . | Data . |
|---|---|
| Sex, no. patients | |
| Male | 16 |
| Female | 13 |
| Median age, y (range) | 73 (67-82) |
| Median ECOG performance status, (range) | 1 (1-3) |
| Median d from diagnosis to trial entry (range) | 21 (6-166) |
| FAB type, no. patients | |
| MO | 2 |
| M1 | 7 |
| M2 | 7 |
| M4 | 6 |
| M5 | 1 |
| M6 | 3 |
| Not classified | 3 |
| Cytogenetic risk group, no. patients | |
| Adverse | 5 |
| Intermediate | 23 |
| Favorable | 1 |
| FLT3 mutation status, no. patients | |
| Internal tandem duplication mutation | 2 |
| Tyrosine kinase domain mutation | 3 |
| Wild type | 24 |
| Median presenting WBC count, × 109/L (range) | 6.1 (0.8-140.7) |
| Prior therapy, no. patients | |
| Oral hydroxyurea | 5 |
| No prior treatment | 24 |
FAB indicates French-American-British classification.